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Abstract
Objectives We studied the feasibility of high-resolution T2-
weighted cervical cancer imaging on an ultra-high-field 7.0-
T magnetic resonance imaging (MRI) system using an
endorectal antenna of 4.7-mm thickness.
Methods A feasibility study on 20 stage IB1–IIB cervical
cancer patients was conducted. All underwent pre-treatment
1.5-T MRI. At 7.0-T MRI, an external transmit/receive array
with seven dipole antennae and a single endorectal monopole
receive antenna were used. Discomfort levels were assessed.
Following individualised phase-based B1
+ shimming, T2-
weighted turbo spin echo sequences were completed.
Results Patients had stage IB1 (n = 9), IB2 (n = 4), IIA1 (n =
1) or IIB (n = 6) cervical cancer. Discomfort (ten-point scale)
was minimal at placement and removal of the endorectal an-
tenna with a median score of 1 (range, 0–5) and 0 (range, 0–2)
respectively. Its use did not result in adverse events or pre-
term session discontinuation. To demonstrate feasibility, T2-
weighted acquisitions from 7.0-T MRI are presented in com-
parison to 1.5-T MRI. Artefacts on 7.0-T MRI were due to
motion, locally destructive B1 interference, excessive B1 un-
der the external antennae and SENSE reconstruction.
Conclusions High-resolution T2-weighted 7.0-T MRI of
stage IB1–IIB cervical cancer is feasible. The addition of an
endorectal antenna is well tolerated by patients.
Key Points
• High resolution T2-weighted 7.0-T MRI of the inner female
pelvis is challenging
• We demonstrate a feasible approach for T2-weighted
7.0-T MRI of cervical cancer
• An endorectal monopole receive antenna is well tolerated by
participants
• The endorectal antenna did not lead to adverse events or
session discontinuation
Keywords Uterine cervical neoplasms .Magnetic resonance
imaging . Feasibility studies . Antenna . Neoplasm staging
Introduction
Accurate staging of cervical cancer is crucial for treatment
planning and determines prognosis. Historically, to allow ef-
ficient and comparable staging in high incidence underdevel-
oped areas, the International Federation of Gynaecology and
Obstetrics (FIGO) requires clinical (i.e. non-surgical) staging
by physical examination [1]. This inherently introduces
understaging and overstaging, particularly for intermediate
stages wherein estimation of (subtle) parametrial invasion by
rectovaginal examination remains difficult, yet determines op-
erability [2]. Studies comparing clinical and post-surgical his-
tological stages in IB1, IB2, IIA1-2 and IIB have reported
concordance in 82–85 %, 61–77 %, 35–60 % and 20–59 %
of cases, respectively [2–4].
Following the 2009 FIGO update, and supported by
(inter)national guidelines, magnetic resonance imaging
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(MRI) may be added to the work-up to assist clinical staging
[5–7]. A meta-analysis (n = 3,254, 40 studies) showed a
pooled sensitivity of 84 % for detection of parametrial inva-
sion by MRI, substantially superior to the 40 % achieved by
clinical examination [8]. This study also identified higher B0
field strengths and the use of fast spin echo sequences as
statistically significant factors to improve the accuracy in de-
tecting parametrial invasion [8].
Increasing the B0 field strength to 7.0 T, increases the
signal-to-noise ratio (SNR) and consequently allows for
higher spatial or temporal resolution acquisitions [9]. While
more expensive, this is potentially advantageous for the as-
sessment of loco-regional invasion which is a predominantly
anatomic, spatial resolution-dependent assessment made on
T2-weighted MR images. Moreover, at 7.0 T, the MRI signals
are obtained at much shorter wavelengths than at lower fields,
facilitating the use of ultra-thin antennae [10]. While using
such an antenna in close proximity to the cervix is more labo-
rious, SNR and thereby resolution is expected to increase even
further.
We built an endorectal monopole antenna and aimed to
develop dedicated T2-weighted TSE sequences for 7.0-T im-
aging with that antenna combined with an external coil array,
to image the (para)cervical anatomy in early stage cervical
cancer patients. To date, no published research exists which
has attempted this. We assessed patient tolerance of using an
endorectal antenna. In addition, wewill present the T2-weight-




We conducted a monocentre, prospective cohort study to de-
velop, optimise and assess the feasibility of high-resolution
pelvic T2-weighted in vivo imaging on a 7.0-T MRI system
using a purpose-designed endorectal antenna. Inclusion
criteria were: (1) a histologically proven primary malignancy
of the cervix uteri, (2) FIGO stage IB1, IB2, IIA1-2 or IIB
disease, and (3) a minimum age of 18 years. Patients were
excluded when (1) general contra-indications for MRI existed,
(2) radical surgery had already been performed or chemother-
apy and/or radiotherapy had been initiated, or (3) uterine pro-
lapse existed (C ≥ −6 cm, POP-Q classification [11]). When
eligible, subjects were consecutively counselled between
March 2014 and November 2015.
The institutional review board approved this study
(clinicaltrials.gov: NCT02083848). Participants provided
written informed consent. Data quality, protocol adherence
and safety were independently monitored by qualified staff.
At our tertiary oncologic referral centre, clinical staging
adheres to FIGO and national cervical cancer guidelines [1,
6]. ESM 1 provides details on the clinical 1.5-T MRI and
treatment [12].
7.0-T MRI
Participants completed a safety checklist and underwent metal
detector testing prior to imaging on a whole-body 7.0-T MRI
system (Achieva; Philips Medical Systems, Cleveland, USA)
equipped with eight-channel multi-transmit functionality.
Intravenous contrast agents were not administered, nor was
spasmolytic medication. Adverse events were monitored in
adherence to the common terminology criteria for adverse
events criteria [13].
The shortened B1 wavelength at ultra-high-field MRI,
which limits signal penetration and increases the risk of de-
structive interference, challenges cervical cancer imaging giv-
en its anatomical position deep in the female inner pelvis. To
alleviate these issues, a local transmit/receive array consisting
of seven 30-cm fractionated dipole antennae (MR Coils,
Drunen, Netherlands) was used. This setup allows for per
patient optimisation of the B1 field distribution. The technical
specifications of this array, including the corresponding spe-
cific absorption rate (SAR) implications, were recently pub-
lished [14].
The internal monopole B1 receive antenna was created in-
house and specifically designed for endorectal use in 7.0-T
MRI, and subsequently commercialised by Machnet (Maarn,
Netherlands). It was positioned in a 14-Fr Foley urinary cath-
eter with a desufflated balloon for an optimal balance between
rigidity and flexibility, yielding a 4.7-mm outer diameter
(Fig. 1). In addition to its sterilisation in-between sessions, a
single-use, sterile cover (Ultracover 200 mm; Microtek
Medical, Zutphen, Netherlands) was used. Water-based lubri-
cating gel (K-Y; Johnson & Johnson, Sézanne, France) facil-
itated easy endorectal positioning. The region with optimal
signal strength was located 6–10 cm beyond the anal verge.
Patient-reported levels of discomfort related to the antenna—
on a Likert scale from 0 (i.e. none whatsoever) to 10 (i.e. worst
imaginable)—were assessed directly after introduction and
removal.
Sequence parameters were optimised for each patient in the
first half of the study. From inclusion 10 and on, a
standardised protocol with only minor individual adaptations
was used. After a multidirectional survey was obtained for
anatomical localisation, phase-based B1
+ shimming was per-
formed per patient to maximise and homogenise the B1
+ on
the (para)cervical anatomy [15]. Herein, a single-slice gradient
echo sequence was repeated 7 times, each time transmitting
with a different transmit antenna, while receiving with all
eight antennae. Next, following a shimmed survey, T2-weight-
ed TSE sequences in the transverse (repetition time (TR)/echo
time (TE) = 7,000/100 ms, radiofrequency (RF) echo train
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length = 16, flip angle = 90 degrees, matrix = 640 × 640, field
of view (FoV) = 250 × 400 × 59 mm, slice thickness/gap =
3/1 mm, duration = 294 s) and sagittal plane (TR/TE = 7,000/
100 ms, RF echo train length = 16, flip angle = 90 degrees,
matrix = 640 × 640, FoV = 250 × 400 × 73 mm, slice
thickness/gap = 3/1 mm, duration = 294 s) were created.
Also, a T2-weighted TSE axial oblique sequence (TR/TE =
7,000/100 ms, RF echo train length = 16, flip angle = 90
degrees, matrix = 512 × 512, FoV = 350 × 250 × 39 mm, slice
thickness/gap = 3/1 mm, duration = 322 s) angled perpendic-
ular to the cervical canal was performed. All T2-weighted
acquisitions had a voxel size of 0.7 × 0.8 × 3.0 mm and used
a SENSE parallel acquisition technique (parallel reduction
factor, 3). All sequences remained within the maximum local
SAR limit of 10 W/kg [16].
Results
Endorectal antenna tolerance
Of the 25 women who waived participation, only one chose
not to partake because of objections against the use of the
endorectal antenna. In addition to the predetermined sample
of 20 patients, three women provided informed consent but
could not be imaged due to system unavailability. See ESM 2
for the corresponding flowchart. The baseline characteristics
of the scanned population are outlined in Table 1.
Tolerance of the endorectal antenna was excellent, dis-
comfort on the ten-point scale was ‘minimal’ at placement
with a median score of 1 (range, 0–5) and reported as
‘none whatsoever’ for removal with a median score of 0
(range, 0–2). The single outlier of 5 at placement occurred
in a patient who had undergone ligation of multiple
haemorrhoids 1 month earlier. In contrast, a subject with
a history of excisional haemorrhoidectomy 4 years earlier
had uneventful placement (score, 0) and removal (score,
1). Comparable results were found in cases with irritable
bowel syndrome, chronic obstipation and deep infiltrating
endometriosis.
None of the participants reported pain or a heating
sensation at any time, nor did any subject request pre-
term termination of the MRI session. The duration in the
MRI with the antenna in situ was 48.0 ± 7.3 min. One
adverse event—unrelated to the antenna—was reported,
namely <30 s of mild vertigo upon entering the 7.0-T
MRI bore.
Cervical cancer imaging
Key to our focus on T2-weighted imaging was the visual-
isation of parametrial invasion, which is particularly chal-
lenging when subtle and in large tumours. Here, we pres-
ent three exemplary cases which represent the range of
physical examination and imaging results encountered.
First, Fig. 2 presents a woman in whom the physical ex-
amination led to a stage IB2, in agreement with 1.5-T and
7.0-T MRI which indicated bilaterally absent parametrial
invasion. The second example was clinically staged as
IB2, though right-sided parametrial invasion was
suspected on both MRIs (Fig. 3). This was motivated by
unclear tumour demarcation against the parametrial fat on
the right—more distinct on 7.0-T MRI—and a locally
interrupted T2-hypointense fibrostromal ring. The third
example was a bulky IIB based on left sided parametrial
invasion at rectovaginal examination. However, the 7.0-T
MRI was considered suggestive of bilateral parametrial
invasion (Fig. 4). All three cases received chemoradiation,
Fig. 1 a Overview of the monopole antenna shown with the 14-Fr Foley
urinary catheter (arrow) removed. b Transverse T2-weighted 7.0-T MRI
of the inner female pelvis which demonstrates the close proximity of the
endorectal monopole antenna (broad arrow) to this stage IB2 poorly
differentiated papillary squamotransitional cell carcinoma (asterisk) of
the cervix. Note the uterine fundus (F) and the T2 hypointense
fibrostromal ring surrounding the tumour (narrow arrows) indicative of
absent parametrial invasion
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hence no definitive histological proof of invasion was
provided. The mean interval between the clinical 1.5-T
and experimental 7.0-T MRI was 13.7 ± 11.8 days.
None of the nine included women with a clinical stage
IB1 tumour had an unexpected histological finding of
parametrial invasion following their radical surgery.
A prior loop excision, sharp conisation or both were per-
formed in three, one and two women, respectively. The inter-
val of this surgery to the clinical 1.5-T and 7.0-T MRI was a
median 42 days (range, 32–44 days) and 47 days (range, 41–
57 days) respectively. After radical surgery, final histology did
not show residual invasive tumour in any of these cases.
Table 1 Baseline characteristics
of the 20 women who underwent
7.0-T MRI
Median age (range) 39.3 (25.3–66.5) years
Median BMI (range) 22.3 (18.4–36.7) kg/m2
n (percentage)
Parity
0 9 (45 %)
1 3 (15 %)
2 8 (40 %)
WHO performance status
0 17 (85 %)
1 3 (15 %)
ASA classification
1 13 (65 %)
2 7 (35 %)
Stage
IB1 9 (45 %)
IB2 4 (20 %)
IIA1 1 (5 %)
IIB 6 (30 %)
Tumour histology
Squamous cell carcinoma 10 (50 %)
Adenocarcinoma 8 (40 %)
Other 2 (10 %)
Tumour differentiation
Grade 1 3 (15 %)
Grade 2 8 (40 %)
Grade 3 7 (35 %)
Not applicable 2 (10 %)
LVSI present 5 (25 %)
Lymph node metastasesa 4 (20 %)
Treatment
Robot ass. laparoscopic SLN + PLND + RVT or RH 7 (35 %)
Robot ass. laparoscopic SLN + PLND + RH + adjuvant Rthb 1 (5 %)
Robot ass. laparoscopic SLN + PLND + chemoradiationc 1 (5 %)
PLND + RH via laparotomyd 1 (5 %)
Chemoradiation 10 (50 %)
BMI body mass index, WHO World Health Organisation, ASA American Society of Anaesthesiologists, LVSI
lymphvascular space invasion, SLN sentinel lymph node procedure, PLND pelvic lymph node dissection, RVT
radical vaginal trachelectomy, RH radical hysterectomy, Rth radiotherapy
aDetermined by a composite of the SLN procedure, PLND or PET-CT as available
b Adjuvant radiotherapy was indicated due to a <5-mm resection margin
c Chemoradiation substituted radical hysterectomy because of intraoperatively detected tumour-positive sentinel
lymph nodes
d After diagnosis and staging at our centre, this patient preferred treatment at a different hospital where no
laparoscopic radical surgery was performed
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Artefacts
On sagittal acquisitions, motion artefacts in the phase
encoding direction, caused by breathing, occurred relatively
frequently (Fig. 5a). Secondly, non-essential anatomical re-
gions were variably obscured by signal voids caused by de-
structive interference of B1—due to the short RF wavelength
at 7.0 T—from the multiple independent external transmit
antennae (Fig. 5b). Thirdly, superficial black semicircular in-
version bands were present due to the inherently much higher
B1 levels directly under the elements of the external transmit/
receive antenna array (Fig. 5c). While encountered in all
participants, it posed no clinical problem as only the subcuta-
neous fat was obscured. Fourthly, small SENSE reconstruc-
tion artefacts were incidentally seen, and are likely caused by
destructive interference in the receive signals of the SENSE
reference scan (Fig. 5d).
Discussion
This feasibility study showed that T2-weighted cervical
cancer imaging at 7.0 T is achievable and that the in-
corporation of an endorectal antenna is well tolerated by
Fig. 2 a Mid-sagittal and b axial oblique (perpendicular to the cervical
canal) T2-weighted slice at 7.0 Tof a 44-year-old patient diagnosed with a
70-mm, stage IB2, poorly differentiated squamous cell carcinoma
originating from the ventral part of the cervix. Note the visible biopsy
site (arrow). c Slice from the same sequence, though 12 mm cranially, as
b, depicting part of the healthy (T2 hypointense) cervix invaded by
tumour. d Axial oblique T2-weighted slice from the clinical 1.5-T MRI,
created 17 days earlier, matched to c for comparison. Note the T2
hypointense fibrostromal ring surrounding the tumour
Fig. 3 a Sagittal and b axial oblique T2-weighted acquisitions from the
7.0-T MRI of a 48-year-old woman diagnosed with an 80-mm poorly
differentiated squamous cell carcinoma of the dorsal cervix. c. Slice from
the same acquisition as b, though positioned 12mm cranially. Parametrial
invasion was judged absent at rectovaginal palpation, leading to a clinical
stage IB2. However, the unclear tumour demarcation and absent T2
hypointense fibrostromal ring on the right (arrows) are suggestive of
right-sided parametrial invasion (i.e. stage IIB). d-f The matched T2-
weighted axial oblique slices from the clinical 1.5-T MRI, created
24 days earlier, are provided for comparison
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patients. We have presented the acquired images, refer-
enced against 1.5-T MRI, relevant for local tumour as-
sessment. To our knowledge, no literature currently ex-
ists on 7.0-T MRI in cervical cancer, which in the past
has been termed ‘a considerable challenge’ [17]. The
presented study demonstrates a feasible approach to
body imaging for pathology in the female pelvis.
Earlier research on 7.0-T MRI in the female pelvis was
obtained with an external coil array only, limited to healthy
volunteers and reported moderate image quality of T2-weight-
ed sequences [18]. Our approach incorporated an endorectal
monopole antenna for optimal signal capture, improving the
SNR, deep in the inner pelvis [19]. Its use was not judged as
uncomfortable, nor did it prohibit study accrual. Furthermore,
Fig. 4 a Transverse T2-weighted acquisition from the 7.0-TMRI of a 65-
year-old woman diagnosed with a 50-mm moderately differentiated
squamous cell carcinoma of the cervix. b Slice from the same
acquisition as a, though positioned 8 mm cranially. Only left-sided
parametrial invasion was judged present at rectovaginal palpation,
leading to a clinical stage IIB. However, the bilaterally unclear tumour
demarcation and absent T2 hypointense fibrostromal ring are suggestive
of bilaterally sided parametrial invasion (arrows). c, d The matched
transverse T2-weighted slices from the clinical 1.5-TMRI, created 16 days
earlier, are provided for comparison. Note the free fluid in the
rectouterine pouch (Douglas)
Fig. 5 Image artefacts that were
encountered on 7.0-TMRI were a
motion artefacts, b locally
destructive B1 interference, c
inversion bands due to too much
B1 under the external transmit/
receive antennae and d SENSE
reconstruction artefacts. Note the
unrelated vaginal tampon
(asterisk) in c
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in our small sample, no adverse events related to the antenna
were encountered.
The research group led by Nandita deSouza has published
extensively on their in-house built 37-mm ring-shaped sole-
noid receive coil, placed endovaginally around the cervix, for
0.5- to 3.0-TMRI in stage IA, IB1 and IIA cervical cancer [20,
21]. Its application appears limited to relatively small lesions,
though accurate in tumour detection and volume calculation
[22–24]. Unfortunately, for parametrial invasion detection on
T2-weighted imaging no conclusions have thus far been
reached on the added value of this solenoid receive coil [25].
In a recent study on radical surgery (n = 25), only one patient
had unexpected parametrial extension which was missed on
MRI with the solenoid receive coil [25].
In line with the above, a limitation of our study is that none
of the women clinically suspected of parametrial invasion had
histological confirmation. The risk of partial verification bias
is inherent to current practice guidelines, which preclude rad-
ical surgery for women with tumour extension outside the
cervix [6, 7, 26]. While definitive proof would have strength-
ened our case presentation, this was prohibited by the inherent
design of our study which was not aimed at diagnostic
accuracy.
Several technical challenges in our study on pelvic im-
aging at ultra-high field strength merit further explanation.
The SNR advantage of the endorectal antenna is local,
which limits the high-resolution field of view in the
feet-head direction and does not—for example—permit
enhanced visualisation of lymph nodes at the common
iliac arteries [19]. While relevant for a clinical MRI pro-
tocol, this was not an objective of the current study, which
focused on the feasibility of primary tumour imaging.
Secondly, at ultra-high field strengths the tissue RF power
deposition is substantial and, in RF pulse intensive se-
quences like TSE used for T2-weighted imaging, leads
to SAR constraints. As a consequence, the repetition time
has to be increased, which lengthens the scan protocol.
Internal antennae may, however, alleviate this by taking
advantage of its highly non-uniform spatial field distribu-
tion that can be used for zoomed imaging or high imaging
accelerations [14]. In addition, the short B1 wavelength at
ultra-high field strengths causes B1 inhomogeneity and
destructive interference, yielding artefacts which may ob-
scure relevant parts of the inner pelvic anatomy. Using
multi-dimensional RF pulses, these artefacts may be re-
moved [27]. Our individualised B1 shimming approach,
made possible by using an external body array coil with
multiple elements in parallel transmission, ensured that
key anatomical regions of interest (i.e. the cervix)
remained visible. Finally, the SENSE reconstruction algo-
rithm that was implemented by the manufacturer, uses at
the time of the study a reference scan with a constant
amplitude and phase weighting during reception. This
can cause destructive interferences during reception, caus-
ing artefacts (Fig. 5d). These artefacts can be mitigated
using interferometry techniques [28].
Future studies should focus on whether our experimental
imaging technique improves clinical decision making. This
includes quantifying both the diagnostic test accuracy and
observer variability (i.e. reproducibility). Furthermore, we fo-
cused on T2-weighted imaging as it is relevant for local tu-
mour assessment, though for clinical implementation addi-
tional sequences such as T1-weighted MRI are desired [29].
The addition of functional imaging such as 1H or 31P MR
spectroscopy—current experience in cervical cancer is limited
to 1.5- to 3.0-TMRI—may benefit from the increased spectral
and spatial resolution at ultra-high B0 field strengths [30, 31].
In conclusion, the use of an endorectal monopole antenna
to improve the SNR at the level of the cervix was well toler-
ated by participants and not associated with any real discom-
fort, nor did it lead to adverse events or hinder study accrual.
We established the feasibility of T2-weighted cervical cancer
imaging with 7.0-T MRI. While further research is needed to
reduce artefacts and substantiate its clinical impact, we dem-
onstrated that high-resolution T2-weighted acquisitions deep
in the female pelvis can be achieved with ultra-high-field
MRI. This combination of ultra-high-field MRI and an inter-
nal antenna is promising and merits further research, including
pelvic imaging for indications beyond cervical cancer.
Acknowledgements The scientific guarantor of this publication is WB
Veldhuis, MD PhD. The authors of this manuscript declare relationships
with the following companies: DWKlomp has an interest of 4.9 % inMR
Coils BV.
This study has received funding by the Dutch government via the
STW (Stichting Technische Wetenschappen) technology foundation for
the development of the endorectal monopole antenna (grant 10822).
Institutional Review Board approval was obtained (reference:
NL41056.041.13). Written informed consent was obtained from all sub-
jects (patients) in this study. Methodology: prospective, experimental,
performed at one institution.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. FIGO Committee on Gynecologic Oncology (2014) FIGO staging
for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol
Obstet 125:97–98
2. QuinnM, Benedet J, Odicino F et al (2006) Carcinoma of the cervix
uteri. FIGO 26th Annual Report on the Results of Treatment in
Gynecological Cancer. Int J Gynecol Obstet 95(Suppl 1):S43–S103
Eur Radiol (2017) 27:9 8–943 5944
3. Qin Y, Peng Z, Lou J et al (2009) Discrepancies between clinical
staging and pathological findings of operable cervical carcinoma
with stage IB-IIB: a retrospective analysis of 818 patients. Aust
NZJ Obstet Gynaecol 49:542–544
4. LaPolla JP, Schlaerth JB, Gaddis O, Morrow CP (1986) The influ-
ence of surgical staging on the evaluation and treatment of patients
with cervical carcinoma. Gynecol Oncol 24:194–206
5. Odicino F, Tisi G, Rampinelli F et al (2007) New development of
the FIGO staging system. Gynecol Oncol 107(1 Suppl 1):S8–S9
6. Guideline cervical cancer, version 3.0, subsection; diagnostics.
Available at www.oncoline.nl, a website from the Integraal
kankercentrum Nederland (IKNL). Accessed 15 January 2014
7. NCCN Clinical practice guideline in oncology. Cervical cancer.
Version 3.2013. Available at www.nccn.org. Accessed 20 January
2014
8. ThomeerMG, Gerestein C, Spronk S, van Doorn HC, van der Ham
E, Hunink MG (2013) Clinical examination versus magnetic reso-
nance imaging in the pretreatment staging of cervical carcinoma:
systematic review and meta-analysis. Eur Radiol 23:2005–2018
9. Kuhl CK, Träber F, Schild HH (2008) Whole-body high-field-
strength (3.0-T) MR Imaging in Clinical Practice. Part I.
Technical considerations and clinical applications. Radiology 246:
675–696
10. Ertürk MA, El-Sharkawy AM, Bottomley PA (2008) Interventional
loopless antenna at 7 T. Magn Reson Med 68:980–988
11. Bump RC, Mattiasson A, Bø K et al (1996) The standardization of
terminology of female pelvic organ prolapse and pelvic floor dys-
function. Am J Obstet Gynecol 175:10–17
12. Hoogendam JP, Verheijen RH, Wegner I, Zweemer RP (2014)
Oncological outcome and long-term complications in robot-
assisted radical surgery for early stage cervical cancer: an observa-
tional cohort study. BJOG 121:1538–1545
13. National Cancer Institute, US department of health and human ser-
vices. Common Terminology Criteria for Adverse Events
(CTCAE), version 4.03. Available at http://evs.nci.nih.gov.
Accessed 31 May 2013
14. Raaijmakers AJ, Italiaander M, Voogt IJ et al (2016) The fraction-
ated dipole antenna: A new antenna for body imaging at 7 Tesla.
Magn Reson Med 75:1366–1374
15. Metzger GJ, Snyder C, Akgun C, Vaughan T, Ugurbil K, van de
Moortele PF (2008) Local B1+ shimming for prostate imaging with
transceiver arrays at 7T based on subject-dependent transmit phase
measurements. Magn Reson Med 59:396–409
16. International Commission on Non-Ionizing Radiation Protection
(2004) Medical magnetic resonance (MR) procedures: protection
of patients. Health Phys 87:197–216
17. Norris DG (2003) High field human imaging. J Magn Reson
Imaging 18:519–529
18. Umutlu L, Kraff O, Fischer A et al (2013) Seven-Tesla MRI of the
female pelvis. Eur Radiol 23:2364–2373
19. Kalleveen IM, Hoogendam JP, Raaijmakers AJ et al. (2015)
Boosting SNR with an internal antenna and external antennae in
the human cervix uteri in TSE at 7 T. Available at http://www.
ismrm.org/14/program_files/EP05.htm. Accessed 27 November
2015
20. Charles-Edwards EM, Messiou C, Morgan VA et al (2008)
Diffusion-weighted imaging in cervical cancer with an endovaginal
technique: potential value for improving tumor detection in stage Ia
and Ib1 disease. Radiology 249:541–550
21. deSouzaNM,ScoonesD,KrauszT,GilderdaleDJ,SoutterWP(1996)
High-resolutionMR imaging of stage I cervical neoplasia with a ded-
icated transvaginal coil: MR features and correlation of imaging and
pathologic findings. AJRAm JRoentgenol 166:553–559
22. Soutter WP, Hanoch J, D'Arcy T, Dina R, McIndoe GA, DeSouza
NM (2004) Pretreatment tumour volume measurement on high-
resolution magnetic resonance imaging as a predictor of survival
in cervical cancer. BJOG 111:741–747
23. deSouza NM, Whittle M, Williams AD et al (2000) Magnetic res-
onance imaging of the primary site in stage I cervical carcinoma: a
comparison of endovaginal coil with external phased array coil
techniques at 0.5T. J Magn Reson Imaging 12:1020–1026
24. deSouza NM, McIndoe GA, Soutter WP et al (1998) Value of
magnetic resonance imaging with an endovaginal receiver coil in
the pre-operative assessment of Stage I and IIa cervical neoplasia.
BJOG 105:500–507
25. Downey K, Attygalle AD, Morgan VA et al (2016) Comparison of
optimised endovaginal vs external array coil T2-weighted and
diffusion-weighted imaging techniques for detecting suspected ear-
ly stage (IA/IB1) uterine cervical cancer. Eur Radiol 26:941–950
26. Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C
(2012) Cervical cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):
vii27–vii32
27. Malik SJ, Keihaninejad S, Hammers A, Hajnal JV (2012) Tailored
excitation in 3D with spiral nonselective (SPINS) RF pulses. Magn
Reson Med 67:1303–1315
28. Brunner DO, Pruessmann KP (2009) B1(+) interferometry for the
calibration of RF transmitter arrays. Magn Reson Med 61:1480–
1488
29. Balleyguier C, Sala E, Da Cunha T et al (2011) Staging of uterine
cervical cancer with MRI: guidelines of the European Society of
Urogenital Radiology. Eur Radiol 21:1102–1110
30. Payne GS, Schmidt M, Morgan VA et al (2010) Evaluation of
magnetic resonance diffusion and spectroscopy measurements as
predictive biomarkers in stage 1 cervical cancer. Gynecol Oncol
116:246–252
31. Booth SJ, Pickles MD, Turnbull LW (2009) In vivo magnetic res-
onance spectroscopy of gynaecological tumours at 3.0 Tesla. BJOG
116:300–303
Eur Radiol (2017) 27:9 8–943 5 945
